The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI).
 
Jose Mauricio Mota
No Relationships to Disclose
 
Min Yuen Teo
Research Funding - Bristol-Myers Squibb
 
Karissa Whiting
No Relationships to Disclose
 
Irina Ostrovnaya
No Relationships to Disclose
 
Han Li
No Relationships to Disclose
 
Chung-Han Lee
Consulting or Advisory Role - Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Eisai
 
Samuel Aaron Funt
Stock and Other Ownership Interests - Allogene Therapeutics; Hubble (I); Kite, a Gilead company; Neogene Therapeutics (I); Second Science; Urogen pharma (I)
Consulting or Advisory Role - MedImmune
Research Funding - AstraZeneca; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Gopa Iyer
Consulting or Advisory Role - Bayer
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EMD Serono; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Pfizer; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Astellas Pharma; AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech; Urogen pharma
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Medscape; Peerview; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; Inovio Pharmaceuticals; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Sanofi; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Agensys (Inst); AstraZeneca; Bayer (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche